CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 78.1% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
1.20
6.19%
  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
Trading сonditions
Spread 0.05
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.026179 %
Charges from full value of position ($-4.97)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.026179%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.003957 %
Charges from full value of position ($0.75)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.003957%
Overnight fee time 21:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Key Stats
Prev. Close* 1.13
Open* 1.12
1-Year Change* -59.12%
Day's Range* 1.12 - 1.2
52 wk Range 0.53-5.75
Average Volume (10 days) 74.69K
Average Volume (3 months) 1.78M
Market Cap 11.23M
P/E Ratio -100.00K
Shares Outstanding 10.69M
Revenue N/A
EPS -0.95
Dividend (Yield %) N/A
Beta -100.00K
Next Earnings Date Feb 29, 2024

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Apr 18, 2024 1.20 0.08 7.14% 1.12 1.20 1.12
Apr 17, 2024 1.13 0.03 2.73% 1.10 1.15 1.08
Apr 16, 2024 1.10 -0.02 -1.79% 1.12 1.16 1.10
Apr 15, 2024 1.16 -0.01 -0.85% 1.17 1.21 1.12
Apr 12, 2024 1.20 -0.01 -0.83% 1.21 1.21 1.17
Apr 11, 2024 1.22 0.06 5.17% 1.16 1.26 1.16
Apr 10, 2024 1.13 -0.01 -0.88% 1.14 1.15 1.13
Apr 9, 2024 1.12 -0.02 -1.75% 1.14 1.17 1.10
Apr 8, 2024 1.11 -0.03 -2.63% 1.14 1.52 1.10
Apr 5, 2024 1.11 -0.09 -7.50% 1.20 1.22 1.11
Apr 4, 2024 1.15 -0.05 -4.17% 1.20 1.23 1.15
Apr 3, 2024 1.22 0.00 0.00% 1.22 1.22 1.17
Apr 2, 2024 1.20 -0.06 -4.76% 1.26 1.26 1.17
Apr 1, 2024 1.29 0.02 1.57% 1.27 1.29 1.27
Mar 28, 2024 1.33 0.10 8.13% 1.23 1.33 1.20
Mar 27, 2024 1.34 0.06 4.69% 1.28 1.34 1.28
Mar 26, 2024 1.28 -0.03 -2.29% 1.31 1.31 1.28
Mar 25, 2024 1.35 0.00 0.00% 1.35 1.39 1.35
Mar 22, 2024 1.35 -0.01 -0.74% 1.36 1.38 1.30
Mar 21, 2024 1.38 -0.06 -4.17% 1.44 1.44 1.38

RenovoRx, Inc. Events

Time (UTC) Country Event
Monday, May 13, 2024

Time (UTC)

12:30

Country

US

Event

Q1 2024 RenovoRx Inc Earnings Release
Q1 2024 RenovoRx Inc Earnings Release

Forecast

-

Previous

-
Friday, June 7, 2024

Time (UTC)

16:00

Country

US

Event

RenovoRx Inc Annual Shareholders Meeting
RenovoRx Inc Annual Shareholders Meeting

Forecast

-

Previous

-
Thursday, August 15, 2024

Time (UTC)

12:30

Country

US

Event

Q2 2024 RenovoRx Inc Earnings Release
Q2 2024 RenovoRx Inc Earnings Release

Forecast

-

Previous

-
View all events
  • Annual
  • Quarterly
2022 2021 2020 2019
Total revenue 0 0 0 0
Total Operating Expense 9.95 5.609 3.204 3.896
Selling/General/Admin. Expenses, Total 5.649 2.632 0.818 0.899
Research & Development 4.301 3.039 2.386 2.997
Operating Income -9.95 -5.609 -3.204 -3.896
Interest Income (Expense), Net Non-Operating 0.057 -0.834 -0.587 0.063
Other, Net 0.004 0.119 -0.007 -0.006
Net Income Before Taxes -9.889 -6.324 -3.798 -3.839
Net Income After Taxes -9.889 -6.324 -3.798 -3.839
Net Income Before Extra. Items -9.889 -6.324 -3.798 -3.839
Net Income -9.889 -6.324 -3.798 -3.839
Income Available to Common Excl. Extra. Items -9.889 -6.324 -3.798 -3.839
Income Available to Common Incl. Extra. Items -9.889 -6.324 -3.798 -3.839
Diluted Net Income -9.889 -6.324 -3.798 -3.839
Diluted Weighted Average Shares 9.05173 5.217 8.38437 8.38437
Diluted EPS Excluding Extraordinary Items -1.0925 -1.21219 -0.45299 -0.45788
Dividends per Share - Common Stock Primary Issue 0 0 0
Diluted Normalized EPS -1.0925 -1.22408 -0.45299 -0.45788
Unusual Expense (Income) 0 -0.062
Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
Total revenue 0 0 0 0 0
Total Operating Expense 3.375 3.261 2.17 2.161 2.614
Selling/General/Admin. Expenses, Total 1.45 1.923 1.394 1.315 1.224
Research & Development 1.925 1.338 0.776 0.846 1.39
Unusual Expense (Income) 0 0 0
Operating Income -3.375 -3.261 -2.17 -2.161 -2.614
Interest Income (Expense), Net Non-Operating 0.05 0.004 0.014 0.022 0.02
Other, Net 0.998 0 0 0.003 0
Net Income Before Taxes -2.327 -3.257 -2.156 -2.136 -2.594
Net Income After Taxes -2.327 -3.257 -2.156 -2.136 -2.594
Net Income Before Extra. Items -2.327 -3.257 -2.156 -2.136 -2.594
Net Income -2.327 -3.257 -2.156 -2.136 -2.594
Income Available to Common Excl. Extra. Items -2.327 -3.257 -2.156 -2.136 -2.594
Income Available to Common Incl. Extra. Items -2.327 -3.257 -2.156 -2.136 -2.594
Diluted Net Income -2.327 -3.257 -2.156 -2.136 -2.594
Diluted Weighted Average Shares 10.6552 9.08999 9.08898 9.06751 9.05719
Diluted EPS Excluding Extraordinary Items -0.21839 -0.35831 -0.23721 -0.23557 -0.2864
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS -0.21839 -0.35831 -0.23721 -0.23557 -0.2864
  • Annual
  • Quarterly
2022 2021 2020 2019
Total Current Assets 7.265 16.281 1.91 2.266
Cash and Short Term Investments 6.44 15.192 1.795 2.104
Cash & Equivalents 4.391 15.192 1.795 2.104
Prepaid Expenses 0.825 1.089 0.115 0.142
Other Current Assets, Total 0 0.02
Total Assets 7.265 16.287 1.914 2.27
Other Long Term Assets, Total 0.004 0.004
Total Current Liabilities 1.102 0.938 4.096 0.805
Accounts Payable 0.534 0.525 0.162 0.538
Accrued Expenses 0.568 0.413 0.311 0.232
Notes Payable/Short Term Debt 0 0 2.65 0
Current Port. of LT Debt/Capital Leases 0 0.117 0
Other Current Liabilities, Total 0 0.856 0.035
Total Liabilities 1.102 0.938 4.119 0.805
Total Long Term Debt 0 0 0.023 0
Long Term Debt 0 0.023 0
Total Equity 6.163 15.349 -2.205 1.465
Redeemable Preferred Stock 0 0 12.451 12.391
Common Stock 0.001 0.001 0.001 0.001
Additional Paid-In Capital 37.318 36.632 0.303 0.235
Retained Earnings (Accumulated Deficit) -31.173 -21.284 -14.96 -11.162
Total Liabilities & Shareholders’ Equity 7.265 16.287 1.914 2.27
Total Common Shares Outstanding 9.0977 8.93399 8.38437 8.38437
Property/Plant/Equipment, Total - Net 0 0.006
Short Term Investments 2.049
Other Equity, Total 0.017
Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
Total Current Assets 3.519 6.314 4.561 7.265 9.25
Cash and Short Term Investments 3.226 5.954 3.723 6.44 8.114
Cash & Equivalents 3.226 5.954 3.723 4.391 3.093
Prepaid Expenses 0.252 0.324 0.592 0.825 1.136
Total Assets 3.519 6.314 4.561 7.265 9.25
Other Long Term Assets, Total
Total Current Liabilities 1.605 1.699 1.305 1.102 1.102
Accounts Payable 0.35 0.872 0.828 0.534 0.538
Accrued Expenses 1.255 0.827 0.477 0.568 0.564
Notes Payable/Short Term Debt 0 0 0 0 0
Current Port. of LT Debt/Capital Leases
Other Current Liabilities, Total
Total Liabilities 3.513 5.126 1.305 1.102 1.102
Total Long Term Debt 0 0 0 0 0
Long Term Debt
Total Equity 0.006 1.188 3.256 6.163 8.148
Redeemable Preferred Stock 0 0 0 0 0
Common Stock 0.001 0.001 0.001 0.001 0.001
Additional Paid-In Capital 38.183 37.944 37.685 37.318 37.151
Retained Earnings (Accumulated Deficit) -38.178 -36.757 -34.43 -31.173 -29.017
Total Liabilities & Shareholders’ Equity 3.519 6.314 4.561 7.265 9.25
Total Common Shares Outstanding 10.6931 10.6931 9.13125 9.0977 9.07226
Property/Plant/Equipment, Total - Net 0 0
Short Term Investments 0 0 0 2.049 5.021
Other Equity, Total 0 0 0 0.017 0.013
Other Current Assets, Total 0.041 0.036 0.246
Other Liabilities, Total 1.908 3.427
  • Annual
  • Quarterly
2022 2021 2020 2019
Net income/Starting Line -9.889 -6.324 -3.798 -3.839
Cash From Operating Activities -8.811 -5.916 -3.528 -3.35
Non-Cash Items 0.65 0.673 0.539 0.046
Changes in Working Capital 0.428 -0.265 -0.269 0.443
Cash From Investing Activities -2.032 -0.015 0 -0.001
Other Investing Cash Flow Items, Total -2.032 0 -0.001
Cash From Financing Activities 0.042 19.328 3.199 0
Financing Cash Flow Items 0 0.003 0
Issuance (Retirement) of Stock, Net 0.042 17.351 0.018 0
Issuance (Retirement) of Debt, Net 0 1.977 3.178 0
Net Change in Cash -10.801 13.397 -0.329 -3.351
Capital Expenditures 0 -0.015
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Net income/Starting Line -3.257 -9.889 -7.733 -5.597 -3.003
Cash From Operating Activities -2.706 -8.811 -7.13 -4.458 -2.097
Non-Cash Items 0.115 0.65 0.486 0.343 0.171
Changes in Working Capital 0.436 0.428 0.117 0.796 0.735
Cash From Financing Activities 0.006 0.042 0.039 0.035 0.026
Issuance (Retirement) of Stock, Net 0.006 0.042 0.039 0.035 0.026
Net Change in Cash -0.668 -10.801 -12.099 -12.423 -2.071
Cash From Investing Activities 2.032 -2.032 -5.008 -8
Capital Expenditures 0 0 0
Financing Cash Flow Items
Issuance (Retirement) of Debt, Net 0 0 0
Other Investing Cash Flow Items, Total 2.032 -2.032 -5.008 -8

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

RenovoRx, Inc. Company profile

About RenovoRx Inc

RenovoRx, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for the local treatment of solid tumors. The Company's lead product candidate RenovoGem. Its other product candidate include Renovo Trans-Arterial Micro-Perfusion (RenovoTAMP), and RenovoCath delivery system. RenovoGem, is a drug and device combination consisting of intra-arterial gemcitabine and RenovoCath. Its therapy platform, RenovoRx Trans-Arterial Micro-Perfusion (RenovoTAMP) is focused on optimizing drug concentration in solid tumors using small molecule chemotherapeutics that enable physicians to isolate segments of the vascular anatomy closest to tumors and force chemotherapy across the blood vessel wall to bathe these difficult-to-reach tumors in chemotherapy.

Financial summary

BRIEF: For the nine months ended 30 September 2021, RenovoRx Inc revenues was not reported. Net loss totaled to $4M.

Industry: Medical Equipment, Supplies & Distribution (NEC)

333 W Santa Clara St Ste 900
SAN JOSE
CALIFORNIA 95110
US

Income Statement

  • Annual
  • Quarterly

News

Gold price in 2024: geopolitical tensions and rate-cut expectations keep XAU/USD supported

Investors are keeping a close eye on gold as the conflict in the Middle East escalates with a possibility of a full-scale regional war in the area.

07:56, 17 April 2024

US Earnings Season : JP Morgan, Citigroup, Wells Fargo

The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.

16:03, 11 April 2024

Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues

The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.

09:22, 11 April 2024

US CPI Preview: US inflation expected to grind lower amid fears about sticky prices

US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).

15:11, 9 April 2024

How escalating geopolitical tensions are impacting oil markets

The bullish momentum in oil prices remains strong as escalating geopolitical tensions raise concerns about supply.

13:34, 4 April 2024

A way forward: a roundup of recent central bank decisions

Five of the world’s most significant central banks delivered policy this week. We review the decisions and discuss their impact on the markets.

12:47, 22 March 2024

Bank of Japan Preview: will the BOJ end negative interest rates?

The Bank of Japan meets on Tuesday 19th of March. We preview what to expect from the BOJ decision and how it might impact the USD/JPY and Nikkei 225.

08:44, 18 March 2024

People also watch

Gold

2,389.89 Price
+0.350% 1D Chg, %
Long position overnight fee -0.0190%
Short position overnight fee 0.0108%
Overnight fee time 21:00 (UTC)
Spread 0.30

XRP/USD

0.50 Price
-1.060% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 21:00 (UTC)
Spread 0.01168

BTC/USD

64,297.45 Price
+1.240% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 106.00

US100

17,205.50 Price
-0.770% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0040%
Overnight fee time 21:00 (UTC)
Spread 1.8

Still looking for a broker you can trust?

Join the 610,000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading